FOXO4-DRI (FOXO4-D-Retro-Inverso): Research Overview
Senolytic peptide studied for clearing worn-out cells. Evidence is limited to animal work.
Also known as FOXO4-D-Retro-Inverso
What is FOXO4-DRI?
FOXO4-DRI is a senolytic peptide designed to selectively eliminate senescent 'zombie' cells that accumulate with age and contribute to tissue dysfunction. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive. The 'DRI' modification (D-retro-inverso) uses reversed D-amino acids to increase potency and stability.
What is FOXO4-DRI researched for?
- Selectively induces apoptosis in senescent cells while sparing healthy tissue.
- Restores tissue homeostasis and function in naturally aged animal models.
- Improved fitness, mobility, and physical appearance in aged mice.
- Restored renal function in aged and fast-aging mouse models.
- Improved testicular microenvironment and testosterone secretion in aged mice.
- Removes senescent chondrocytes, potentially benefiting joint health.
- Neutralizes doxorubicin-induced chemotoxicity by clearing treatment-induced senescent cells.
How does FOXO4-DRI work?
FOXO4-DRI competes with FOXO4 for binding to p53, disrupting their protective interaction in senescent cells. This causes p53 to be excluded from the nucleus and triggers cell-intrinsic apoptosis (programmed cell death).
References
Targeted Apoptosis of
Senescent Cells Restores Tissue Homeostasis Cell · 2017
FOXO4-DRI restored fitness, fur density, and renal function in aged mice using 5 mg/kg IP, 3 doses on alternate days. Well-tolerated under therapeutic conditions.
Animal study
An Example of Senolytic Self-Experimentation with FOXO4-DRI Fight Aging!
2017
Self-experimenters have translated the mouse protocol to ~25 mg per injection subcutaneously, 3 doses every other day, for 75-100 mg total per treatment cycle.
Animal study
FOXO4-DRI Alleviates Age-Related Testosterone Secretion Insufficiency Theranostics
2020
FOXO4-DRI improved testicular microenvironment and testosterone secretion by clearing senescent Leydig cells.
FOXO4-DRI Removes Senescent Cells from Human Chondrocytes Frontiers in Bioengineering and Biotechnology
2021
Removed >50% of senescent chondrocytes without affecting healthy early-passage cells.
The Disordered p53 Transactivation Domain is the Target of FOXO4-DRI
Nature Communications · 2025
Structural analysis revealed FOXO4-DRI binds disordered p53TAD2, forming transiently folded complex.
Common questions
What makes FOXO4-DRI different from other anti-aging approaches?
FOXO4-DRI is the first senolytic peptide that selectively eliminates 'zombie' senescent cells accumulating with age, whereas most anti-aging approaches target symptoms or regeneration. It disrupts FOXO4-p53 interaction in senescent cells to trigger apoptosis, effectively removing damaged cells rather than just supporting healthy ones.
What visible changes occurred in aged mice treated with FOXO4-DRI?
Aged mice receiving FOXO4-DRI showed restored fur density, improved physical fitness, enhanced organ function (particularly kidneys), and improved testosterone levels. These dramatic improvements suggest senescent cell clearance genuinely restored tissue homeostasis, though results in humans remain theoretical.